CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

FIRST PATIENT DOSED IN THE PHASE 1/2 CLINICAL TRIAL OF JMT601 IN THE U.S.

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the first patient in the U.S. has been dosed in the Phase 1/2 clinical trial (the "**Study**") of JMT601 (CPO107), a first-in-class drug candidate developed by Shanghai JMT Biotechnology Co., Ltd.* (上海津曼特生物科技有限公司), a subsidiary of the Company.

The Study is a multicenter, first-in-human, dose escalation and dose expansion Phase 1/2 clinical trial conducted in the U.S. to evaluate the safety, pharmacokinetics and preliminary efficacy of JMT601 in the treatment of patients with advanced Non-Hodgkin lymphoma (NHL).

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of lymphoproliferative disorders originating from B lymphocytes, T lymphocytes or NK cells. B-cell lymphomas, which express CD20, make up most (about 85%) of NHLs in the U.S.. While most patients with indolent NHL can live 20 years after diagnosis, those with aggressive lymphomas can have worse prognosis with overall five-year survival rate of around 60%.

** For identification purposes only*

JMT601 (CPO107) is the world's first bispecific SIRPα fusion protein with synergised target binding effect which has entered clinical stage of development. It effectively binds to CD20 on the lymphoma cell surface to induce the antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD20-binding further leads to synergised binding to CD47 expressed on Lymphoma cells, thus abolishing the "don't eat me" signal mediated by CD47 and inducing potent antibody-dependent cellular phagocytosis activity (ADCP) by the macrophages. Its enhanced efficacy as compared with conventional CD20-targeting antibodies was demonstrated in various human B-cell lymphoma models. The nonclinical toxicology studies indicated that JMT601 (CPO107) has no obvious binding with CD20-negative cells, and no significant suppression of strong CD47 positive cells including erythrocytes and thrombocytes was found at a dose of 100 mpk, demonstrating the satisfactory safety profile and supporting the evaluation of JMT601 (CPO107) in clinical studies.

The Group is also conducting a Phase 1 clinical trial of JMT601 in China. Clinical data from these studies will guide the global clinical development of JMT601 (CPO107).

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 14 December 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.